ImmunityBio is on a Mission

To continuously pursue new therapies that kill disease, not the immune system

A Culture Where Patients Come First

The people of ImmunityBio work tirelessly to transform our living biological technologies into innovative treatments that will improve the lives of people around the world. Our goal is to leverage and harmonize with the body’s immune system to clear disease while ensuring our therapies also protect the immune system from damage. ImmunityBio’s major focus is the development of novel treatments for advanced cancers and infectious diseases. We believe our science has the potential to change the current paradigm of care for these diseases.

We do so with a combination of highly experienced and talented people, deep scientific knowledge, and advanced research and manufacturing facilities. Together, they enable us to invent, test, and market innovative, effective, and safe therapies that address some of the greatest needs in medicine. We measure our success by the quality of life we can offer to patients.

Our History

Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases.

Since then we have progressed into a late-stage clinical company with more than 40 Phase I, II, or III clinical trials (company sponsored and investigator initiated) in development across 19 indications in solid and liquid cancers and infectious diseases. Our proprietary natural killer cell platform can be easily expanded, genetically modified, and cryopreserved and offers multiple modes of cytotoxicity. Our lead antibody cytokine fusion protein, Anktiva, has received FDA Breakthrough Therapy designation for one of the most common and difficult to treat types of bladder cancer (BCG-unresponsive non-muscle invasive bladder cancer). Our work is led by a senior team with highly complementary and broad expertise across novel scientific areas including genomics and proteomics, monoclonal antibodies, fusion proteins, vaccines and autologous and allogeneic cell therapy, based on experiences at companies ranging from biotech startups to large commercial pharmaceutical enterprises.

 

Rich Adcock
CEO, ImmunityBio
At ImmunityBio, we never lose sight of who we serve: The patients who depend on us to deliver therapies that will deliver them from serious or fatal diseases. It’s those people that inspire our people, every day.
Dr. Patrick Soon-Shiong
Executive Chairman, ImmunityBio
By 1990, we recognized that the key cell involved in organ rejection following transplantation and in killing cancerous cells was the natural killer cell— nature’s first responder. The discovery of a natural killer cell line by Dr. Hans Klingemann in 1992, dubbed NK-92, set us on the course of natural killer cell therapy for the treatment of cancer and infectious disease.

How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

A Robust Clinical Pipeline

ImmunityBio’s immunotherapies for treating cancer and infectious diseases are currently being studied in a range of clinical trials at various stages.

Meet the Team

Patrick Soon-Shiong, M.D.Executive Chairman of the Board Bio
Rich AdcockChief Executive Officer Bio
David SachsChief Financial Officer Bio
Leonard S. Sender, M.D.Chief Operating Officer Bio
Fabio Benedetti, M.D.Chief Strategy Officer Bio
Sandeep “Bobby” Reddy, M.D.Chief Medical Officer Bio
Sarah SingletonChief Communications Officer Bio
Jason Liljestrom, Esq. General Counsel Bio
Shahrooz Rabizadeh, Ph.D.Chief Science Officer – Fusion Proteins and Neoepitope Bio
Kayvan Niazi
Kayvan Niazi, Ph.D.Chief Science Officer – Immunology and Vaccinology Bio
Barry Simon, M.D.Chief Corporate Affairs Officer Bio
Hans Klingemann, M.D., Ph.D.Chief Science Officer – Cellular Bio
Manju Saxena, Ph.D.Vice President of Product Development, Cell Therapy Program Bio
Elizabeth GabitzschVice President of Product Development, Vaccine Program Bio
Sylvain RoyVice President of Manufacturing Bio

Board of Directors

Patrick Soon-Shiong, M.D.Executive Chairman of the Board Bio
Rich AdcockChief Executive Officer Bio
Michael Blaszyk
Michael Blaszyk Bio
John Brennan Bio
Wesley Clark Bio
Cheryl Cohen Bio
Linda Maxwell
Linda Maxwell, M.D. Bio
Christobel Selecky Bio
Barry Simon, M.D.Chief Corporate Affairs Officer Bio

Deliver access to innovative, disease-altering therapies to those who need them most